APA (7th ed.) Citation

Ying-tao Lin, Tian-xiu Liu, Jian Chen, Chang Wang, & Ying Chen. (2022). Cost-Effectiveness of Nivolumab Immunotherapy vs. Paclitaxel or Docetaxel Chemotherapy as Second-Line Therapy in Advanced Esophageal Squamous Cell Carcinoma in China. Frontiers Media S.A..

Chicago Style (17th ed.) Citation

Ying-tao Lin, Tian-xiu Liu, Jian Chen, Chang Wang, and Ying Chen. Cost-Effectiveness of Nivolumab Immunotherapy Vs. Paclitaxel or Docetaxel Chemotherapy as Second-Line Therapy in Advanced Esophageal Squamous Cell Carcinoma in China. Frontiers Media S.A., 2022.

MLA (9th ed.) Citation

Ying-tao Lin, et al. Cost-Effectiveness of Nivolumab Immunotherapy Vs. Paclitaxel or Docetaxel Chemotherapy as Second-Line Therapy in Advanced Esophageal Squamous Cell Carcinoma in China. Frontiers Media S.A., 2022.